Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
NCT07020832Phase 3Withdrawn
- Sponsor
- Apellis Pharmaceuticals
- Start
- May 2026
- Primary completion
- Jun 2029
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of pegcetacoplan in delayed graft function (DGF), sponsored by Apellis Pharmaceuticals. Planned start May 2026; status: withdrawn.
02
Drugs
pegcetacoplan
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT07020832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020832.